The FDA has authorized Zepbound for treating adults with obesity and moderate to severe obstructive sleep apnea, representing a significant advancement in managing this condition.
In studies, Zepbound produced a 'statistically significant and clinically meaningful reduction' in sleep apnea episodes for those with obesity, benefiting both CPAP users and non-users.
Dr. Sally Seymour emphasized that this approval is a major step forward for obstructive sleep apnea patients, highlighting the importance of weight management in treatment.
The approval of Zepbound aligns with ongoing discussions about the broader applications of weight loss drugs, extending their potential beyond obesity and diabetes.
Collection
[
|
...
]